Other formats:
BibTeX
LaTeX
RIS
@article{1657320,
author = {Máchal, Jan and Hlinomaz, Ota and Kostolanská, Katarína and Peš, Ondřej and Máchalová, Alena and Šplíchal, Zbyněk and Moťovská, Zuzana and Juřica, Jan},
article_location = {Abingdon, UK},
article_number = {8},
doi = {http://dx.doi.org/10.1080/00498254.2020.1731625},
keywords = {Cytochrome P450; prasugrel; ticagrelor; ADP test; aggregation; lansoprazole},
language = {eng},
issn = {0049-8254},
journal = {Xenobiotica},
title = {CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in PRAGUE-18 trial participants},
url = {https://www.tandfonline.com/doi/abs/10.1080/00498254.2020.1731625?journalCode=ixen20},
volume = {50},
year = {2020}
}
TY - JOUR
ID - 1657320
AU - Máchal, Jan - Hlinomaz, Ota - Kostolanská, Katarína - Peš, Ondřej - Máchalová, Alena - Šplíchal, Zbyněk - Moťovská, Zuzana - Juřica, Jan
PY - 2020
TI - CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in PRAGUE-18 trial participants
JF - Xenobiotica
VL - 50
IS - 8
SP - 929-938
EP - 929-938
PB - Taylor & Francis Group
SN - 00498254
KW - Cytochrome P450
KW - prasugrel
KW - ticagrelor
KW - ADP test
KW - aggregation
KW - lansoprazole
UR - https://www.tandfonline.com/doi/abs/10.1080/00498254.2020.1731625?journalCode=ixen20
L2 - https://www.tandfonline.com/doi/abs/10.1080/00498254.2020.1731625?journalCode=ixen20
N2 - We assessed the contribution of CYP2C19 and CYP3A4 metabolic activity to the ADP-induced platelet aggregation 1h and 24h after a loading dose of 60 mg prasugrel or 180 mg ticagrelor in patients with ST-elevation myocardial infarction (STEMI). Further, we assessed the contribution of CYP2C19 polymorphisms and medication to the CYP enzymatic activity. Patients with STEMI were randomly assigned to the treatment with prasugrel (n = 51) or ticagrelor (n = 46). Metabolic activity of CYP2C19 and CYP3A4 was assessed by the rate of 5-hydroxylation and sulfoxidation of lansoprazole. Further, patients were genotyped for CYP2C19 *2 and *17 alleles. In prasugrel-treated patients, high ADP-induced platelet reactivity 1h after the loading dose positively correlated with 5OH-lansoprazole/lansoprazole ratio (r = 0.44, p = 0.002), a marker of CYP2C19 metabolic activity, and negatively with lansoprazole-sulfone/lansoprazole ratio, which reflects CYP3A4 metabolic activity (r = -0.35, p = 0.018). CYP2C19 poor metabolizers had lower 5OH-lansoprazole/lansoprazole ratio and higher lansoprazole-sulfone/lansoprazole ratio, but without any effect on the ADP-induced platelet reactivity. The treatment with amiodarone, a CYP3A4 inhibitor, influenced neither the metabolic ratios nor the ADP-induced platelet reactivity. The CYP3A4 and CYP2C19 metabolic activity is associated with ADP-induced platelet reactivity in prasugrel-treated, but not ticagrelor-treated patients with STEMI.
ER -
MÁCHAL, Jan, Ota HLINOMAZ, Katarína KOSTOLANSKÁ, Ondřej PEŠ, Alena MÁCHALOVÁ, Zbyněk ŠPLÍCHAL, Zuzana MOŤOVSKÁ and Jan JUŘICA. CYP2C19 and CYP3A4 activity and ADP-induced platelet reactivity in prasugrel- or ticagrelor-treated STEMI patients: monocentric study in PRAGUE-18 trial participants. \textit{Xenobiotica}. Abingdon, UK: Taylor \&{} Francis Group, 2020, vol.~50, No~8, p.~929-938. ISSN~0049-8254. Available from: https://dx.doi.org/10.1080/00498254.2020.1731625.
|
